IBTA e-News August 2017 released

By 28th August 2017IBTA News
[28 August 2017] The IBTA's monthly e-News has now been released and has been emailed to all subscribers. To sign up to receive your copy, click here.

You can read the IBTA e-News August 2017 edition in full online here.

Some of the highlights from this month's include:

  • An analysis of medical records over 10 years from an Italian Hospital Emergency Department has revealed the frequency and profile of patients who arrive with an undiagnosed brain tumour "is not a rare occurrence".
  • A study in Nature Communications has given a genetic explanation why childhood brain tumour survivors go on to have an increased risk of meningioma brain tumours in later life.
  • Almost €3.7 million of funding has been awarded to a four-year European initiative called AiPBAND, which will train the next generation of brain tumour researchers, with a focus on glioma.
  • A proof-of-concept study published has shown that it is possible to detect tumour cells in the blood of breast cancer patients that are the 'seeds' of brain metastases, suggesting that a screening tool could be developed to detect when breast cancer is spreading to the brain.
  • Novocure has announced that the Tumor Treating Fields (TTFields) device Optune has been approved for national reimbursement in Austria for the treatment of newly diagnosed glioblastoma in adults, making the therapy available to nearly all of the country's population.
  • The US Food and Drug Administration (FDA) has accepted VBI Vaccines’ Investigational New Drug (IND) application for VBI-1901, a vaccine designed to stimulate an immune response against glioblastoma cells, meaning that a clinical trial of the therapy can proceed later this year.
  • The FDA has awarded orphan drug designation to SurVaxM, a peptide vaccine that targets survivin, a cell-survival protein present in 95% of glioblastomas
  • Our congratulations go to the France-based charity Oscar’s Angels for being awarded the label "Association d'Usagers du Système de Santé" by the French government. This designation means that the charity is now authorised by the government to officially represent "users" (patients and their families) in the hospital commissions and in all Public Health Authorities.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.

To see an archive of existing e-News issues, click here.

Subscribe to IBTA's e-News!